Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SpringWorks Launches With $103m, Four Pfizer Drugs And A Focus On Underserved Patients

Executive Summary

No disease is too small or too large for SpringWorks, which spun out Pfizer with four mid-/late-stage compounds to develop drugs in indications where patients have no good treatment options.

You may also be interested in...



Tech Transfer: BMS, Evotec Partner With Four UK Universities On Translational Research Efforts

The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.

Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific

Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.

ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma

Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel